The FDA has approved the first use of testerotoxins in the treatment of male infertility, a study of male patients reported Thursday in the journal The Lancet.
The drug has been approved for the treatment in more than 200 countries and the FDA expects to approve it for use in the United States in the next two years.
Testerotoxin A was first discovered in the late 1970s in a strain of bacteria called Staphylococcus aureus that causes urinary tract infections.
It was first approved in 1995 for the prevention of urinary tract infection in men with AIDS and for the management of prostate cancer patients with metastatic disease.
The drugs have since been approved to treat a variety of diseases, including a number of autoimmune conditions including Crohn’s disease, psoriasis and rheumatoid arthritis.
The company developing the drug, Gilead Sciences, said in a statement Thursday that the drug “was approved based on evidence of efficacy, safety and tolerability.”
The company said it will make it available through a “targeted open-label” in a few weeks.
The drug is made by a small company based in San Diego, and it has been tested in two large clinical trials to date.
The FDA said the approval for the first drug for the condition is “consistent with the company’s ongoing strategy of expanding its clinical trials and expanding access to these compounds.”
Gilead said the new drug is a novel approach for the control of men with prostate cancer that has been proven to be efficacious in prostate cancer treated with standard treatment regimens, including surgery and radiotherapy.
The new drug works by blocking a protein that helps cells differentiate and that is critical for cell survival in the cancer, the company said.
It works by inhibiting the expression of a key protein called ERK1/2.
ERK2, which is known to play a role in cell proliferation and differentiation, plays a crucial role in the cell’s energy needs.
The ERK inhibitor helps to reduce cell death and inflammation by suppressing the activity of these two key enzymes, which can cause cancer to spread.
In addition to being effective against the disease, the new treatment has also been shown to have other benefits, including improving the immune response in the patients with prostate problems.
The treatment also has been shown in other trials to help reduce inflammation, increase the body’s ability to repair itself and help to restore the body to normal levels of estrogen and progesterone.
Gileady said it plans to start testing the drug in patients with severe prostate cancer and other cancers.
The firm said it expects the treatment to be approved in the U.S. by the end of the year.
The approval of the drug marks the first time that a male-specific compound has been used for prostate cancer treatment.
The compound, known as prostate-specific antigen (PSA), is a hormone produced by the prostate gland and is secreted by the cells that produce it.
In the prostate, it stimulates the growth of prostate-related cells, such as the prostate cancer cells.
The FDA approved the drug for use against the prostate-associated cancer in October of last year.
The agency said in the release that the FDA “considers the use of the compounds to be an option for male patients with benign prostatic hyperplasia (BPH) because of their ability to decrease inflammation and to prevent prostate cancer progression in patients who do not respond to conventional therapy.”
The drug, which was developed by San Diego-based Gileady and New York-based Wyeth-Ayerst Laboratories, was tested in the laboratory in more 200 patients with BPH.
The U.K. drugmaker said the trial “demonstrates the efficacy of this compound in inhibiting prostate-cell-related growth.”